Skip to content
ClinCalc Pro
Menu
Fluoroquinolone antibiotic

Levofloxacin

Brand names: Tavanic

Levofloxacin is a fluoroquinolone antibacterial used for a range of infections including respiratory, urinary and some skin and soft-tissue infections, and as part of certain regimens for resistant tuberculosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription and leading to bacterial cell death.

Prescribing in practice

  • MHRA advice restricts fluoroquinolones to situations where other antibacterials are unsuitable because of rare but serious and potentially irreversible musculoskeletal and nervous-system effects, including tendon rupture and peripheral neuropathy.
  • It prolongs the QT interval and should be used with caution alongside other QT-prolonging drugs and in those with predisposing electrolyte disturbance or cardiac risk.
  • Absorption is markedly reduced by polyvalent cations, so it should be separated in time from antacids, iron, calcium and other multivalent-cation preparations.

Monitoring

Monitor for tendon pain, new neuropathic symptoms and signs of central nervous system effects, with attention to QT risk in susceptible patients.

Counselling the patient

  • Stop the medicine and seek advice if you get tendon pain or swelling, or new numbness, tingling or weakness.
  • Avoid taking it at the same time as indigestion remedies, or iron or calcium supplements.
  • Report any mood changes, confusion or unusual heartbeat sensations.

Evidence & guidelines

MHRA Drug Safety Updates have reinforced restrictions on fluoroquinolone use owing to the risk of disabling and potentially long-lasting adverse effects.

Reference: MHRA Drug Safety Update; UK AMR guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.